Cargando…

Discovery of potent and noncovalent KRAS(G12D) inhibitors: Structure-based virtual screening and biological evaluation

KRAS(G12D), the most common oncogenic KRAS mutation, is a promising target for the treatment of pancreatic cancer. Herein, we identified four potent and noncovalent KRAS(G12D) inhibitors (hits 1–4) by using structure-based virtual screening and biological evaluation. The in vitro assays indicated th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yuting, Zhang, Hai, Li, Jindong, Niu, Miao-Miao, Zhou, Yang, Qu, Yuanqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815544/ https://www.ncbi.nlm.nih.gov/pubmed/36618907 http://dx.doi.org/10.3389/fphar.2022.1094887

Ejemplares similares

Identification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of in vitro and in vivo antitumor activity
por: Yang, Yingxue, et al.
Publicado: (2023)

Discovery of potent heat shock protein 90 (Hsp90) inhibitors: structure-based virtual screening, molecular dynamics simulation, and biological evaluation
por: Xu, Yonghua, et al.
Publicado: (2023)

KRAS inhibitors: going noncovalent
por: Drosten, Matthias, et al.
Publicado: (2022)

Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding
por: McCarthy, Michael J., et al.
Publicado: (2019)

Discovery of Potent Disheveled/Dvl Inhibitors Using Virtual Screening Optimized With NMR-Based Docking Performance Index
por: Hori, Kiminori, et al.
Publicado: (2018)

Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75
por: Yin, Shengnan, et al.
Publicado: (2022)

Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation
por: Tian, Xiaoyan, et al.
Publicado: (2022)

AZD4625 is a Potent and Selective Inhibitor of KRAS(G12C)
por: Chakraborty, Atanu, et al.
Publicado: (2022)

Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells
por: Dong, Xing-Duo, et al.
Publicado: (2022)

Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS(G12C) Inhibitors
por: Luo, Lianxiang, et al.
Publicado: (2022)

QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery
por: Neves, Bruno J., et al.
Publicado: (2018)

Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies
por: Xi, Lili, et al.
Publicado: (2023)

Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
por: Xie, Chun, et al.
Publicado: (2017)

DeepMalaria: Artificial Intelligence Driven Discovery of Potent Antiplasmodials
por: Keshavarzi Arshadi, Arash, et al.
Publicado: (2020)

Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection
por: Xu, Zhen, et al.
Publicado: (2022)

Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening
por: Ge, Huizhen, et al.
Publicado: (2022)

Discovery of METTL3 Small Molecule Inhibitors by Virtual Screening of Natural Products
por: Du, Yue, et al.
Publicado: (2022)

KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
por: Mao, Zhongwei, et al.
Publicado: (2022)

Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists
por: Wang, Lingyan, et al.
Publicado: (2018)

Discovery of New Potent anti-MERS CoV Fusion Inhibitors
por: Kandeel, Mahmoud, et al.
Publicado: (2021)

Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives
por: Li, Meng, et al.
Publicado: (2021)

Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening
por: Wang, Yuwei, et al.
Publicado: (2020)

Identification of PARP12 Inhibitors By Virtual Screening and Molecular Dynamics Simulations
por: Almeleebia, Tahani M., et al.
Publicado: (2022)

D‐1553: A novel KRAS(G12C) inhibitor with potent and selective cellular and in vivo antitumor activity
por: Shi, Zhe, et al.
Publicado: (2023)

Discovery of Quercetin and Its Analogs as Potent OXA-48 Beta-Lactamase Inhibitors
por: Zhang, Yuejuan, et al.
Publicado: (2022)

Target-Based Virtual Screening of Natural Compounds Identifies a Potent Antimalarial With Selective Falcipain-2 Inhibitory Activity
por: Uddin, Amad, et al.
Publicado: (2022)

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS(G12C) Inhibitor
por: Bröker, Joachim, et al.
Publicado: (2022)

Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
por: Luo, Lian-Xiang, et al.
Publicado: (2017)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRAS(G12C)
por: Weiss, Andreas, et al.
Publicado: (2022)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 Through Structure-Based Virtual Screening
por: Zhang, Guoqing, et al.
Publicado: (2018)

Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening
por: Hu, Chujiao, et al.
Publicado: (2022)

Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS(G12D) Mutation
por: Ji, Xiang, et al.
Publicado: (2023)

Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening
por: Diao, Yanyan, et al.
Publicado: (2018)

Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents
por: Liang, Sudong, et al.
Publicado: (2023)

Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods
por: Kulkarni, Apoorva M., et al.
Publicado: (2022)

Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro
por: Hou, Ningke, et al.
Publicado: (2023)

Discovery and Characterization of the Biflavones From Ginkgo biloba as Highly Specific and Potent Inhibitors Against Human Carboxylesterase 2
por: Song, Yun-Qing, et al.
Publicado: (2021)

Identification of a potent dual-function inhibitor for hIMPDH isoforms by computer-aided drug discovery approaches
por: Yazdani, Meysam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4fuj2rsaobgeo2t51lj64au1cl